Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
#分享美股交易赢英伟达股票
Today’s Eli Lilly Stock Market Outlook
Eli Lilly opened with a gap up today, and as of 10:45 AM Eastern Time, the stock price surged +5.72%, trading at $892.50 (yesterday’s close was $844.20). Key driving factors include:
Major New Drug Approval: Alzheimer’s drug Donanemab received full FDA approval, with first-year sales expected to exceed $5 billion
Weight Loss Drug Production Breakthrough: GLP-1 production line expansion completed, weekly capacity increased to 1.5 million doses (up 40% quarter-over-quarter)
Patent Barrier Reinforcement: Court upheld the validity of the Tilaperide patent, delaying competitor market entry until 2030
Technical Indicator Analysis
Trend and Moving Averages:
Stock price broke through the historic $880 gap-up level, with all moving averages (5/10/50/200 days) sharply rising at a 70-degree angle
Formed a classic "island reversal" bullish pattern, with the weekly ascending channel slope accelerating
Momentum Indicators:
RSI soared to 78: Operating in overbought territory but supported by strong volume, no divergence signals
MACD histogram surged: Fast and slow lines widened to the largest value this year, indicating exponential growth in buying momentum
Volume-Price Structure:
Volume traded in the first 90 minutes was 5.8 million shares (three times the monthly average),
In the $880–$890 range, institutional buy orders accounted for 92%
During trading, at $888, a large block buy of 350 million shares appeared, intensifying the main force’s accumulation
Key Support and Resistance Levels:
Support:
$880.00: Gap upper edge + psychological level
$865.00: 5-day moving average dynamic support
Resistance:
$900.00: Whole number level + maximum pain point for options
$915.00: Previous all-time high + gamma squeeze trigger point
Market Outlook
Short-term (Today):
Expected to challenge the $900–$905 range, with key catalysts:
1:30 PM Investor Conference Call: Will disclose Donanemab pricing strategy (expected $26,000/year)
CPI Data Linkage: Cooling inflation benefits biotech valuation expansion
Medium to Long-term (1–3 months):
Growth engine explosion:
✅ ⚠ ✅